Title: Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study

Authors:

Ronald G Hall II (ronald.hall@ttuhsc.edu)
Kathleen A Hazlewood (khazlewo@uwyo.edu)
Sara D Brouse (sara.brouse@uky.edu)
Chris A Giuliano (ek2397@wayne.edu)
Krystal K Haase (krystal.haase@ttuhsc.edu)
Christopher R Frei (freic@uthscsa.edu)
Nicolas A Forcade (nforcade8@gmail.com)
Todd Bell (Todd.Bell@ttuhsc.edu)
Roger J Bedimo (roger.bedimo@va.gov)
Carlos A Alvarez (carlos.alvarez@ttuhsc.edu)

Version: 2 Date: 22 May 2012

Author's response to reviews: see over
May 22, 2012

BMC Clinical Pharmacology

Dr. Morrey:

We have resubmitted, on-line, a Research Article for consideration of publication in the BMC Clinical Pharmacology. The title of the report is ‘Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study’.

We have addressed the following concerns in the manuscript:

1) The abstract should not exceed 350 words and must be structured into separate sections: The abstract is now 291 words and is separated into the defined sections.

2) The methods section should include the design, the setting, type of participants, and the type of analysis used: The methods section has been revised to match the subheadings used in the methods section of BMC Clinical Pharmacology manuscripts.

3) The authors should clearly state the main conclusions of the research and give a clear explanation of their importance and relevance: We have added a conclusions heading to help highlight the summary of our findings. We have also revised the wording of this paragraph to help better inform the reader of the relevance of our findings.

4) There is extensive overlap in the Abstract and Methods sections of this article to similarly titled article in BMC Infectious Diseases: We have worked to provide revised wording for this manuscript.

Please feel free to notify us at the below corresponding author contact information for further inquiry.

Sincerely,

Ronald G. Hall II, PharmD, MSCS, BCPS (Primary and Corresponding Author)
Associate Professor of Pharmacy Practice
Program Director – Dose Optimization and Outcomes Research (DOOR) Program
Texas Tech University Health Sciences Center – School of Pharmacy
5920 Forest Park Rd, Dallas, TX 75216
Phone: 888-406-8671; Fax: 214-654-9707
Email: ronald.hall@ttuhsc.edu